Pediatric Weight Gain From Atypical Antipsychotics Returns To FDA Advisory Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
Panel urged label changes two years ago, but the products still do not include uniform information in their warning sections. FDA is asking its Pediatric Advisory Committee to review the pediatric safety of Bristol/Otsuka's Abilify, along with an AHRQ report on weight gain associated with the class of products.